- Clinical Review Of Minimally Invasive IDET(TM) Procedure Demonstrates Significant Decrease
A meta-analysis of the Intradiscal ELECTROTHERMAL(TM) Therapy (IDET(TM)) procedure examining outcomes of 17 clinical studies demonstrates that patients suffering from chronic disc-related low back pain experience a significant decrease in pain and improvement in physical function, as well as a low incidence of complications. The study is published in the July/August issue of Pain Medicine, the peer-reviewed journal of the American Academy of Pain Medicine. - Qualitative Review Of Chronic Lower Back Pain Clinical Studies Finds Minimally Invasive Procedure
A systematic literature review of outcomes from 51 clinical studies and case series finds that the Intradiscal ELECTROTHERMAL(TM) Therapy (IDET(TM)) procedure would spare up to 65 percent of patients with chronic lower back pain from spinal fusion surgery. In addition, the study also found that IDET patients experienced similar outcome benefits when compared against spinal fusion. - Milestone Scientific Receives FDA Clearance Of Single Tooth Anesthesia Device
Milestone Scientific Inc. (Amex: MSS), which develops, manufactures, and markets 'intelligent' computer controlled local anesthetic delivery systems, today announced that it has received FDA 510(k) Premarket Notification clearance for the marketing and sale of its Single Tooth Anesthesia Device (STA). - NatureWell, Incorporated To Attend Annual American Association Of Naturopathic Physician Convention
NatureWell, Incorporated (the "Company") (OTC Bulletin Board: NAWL), announced today that it will be an exhibitor at the American Association of Naturopathic Physicians (AANP) Annual Convention in Portland, Oregon on August 10-12, 2006, where it will be marketing its natural migraine medication, MigraSpray. Located in Washington, DC and founded in 1985, the AANP is the foremost national professional society representing more than 2000 licensed or licensable naturopathic physicians. - Digital Cameras And Internet Ease The Pain Of Oral Disease For Toddlers
Dental researchers are combining the ease of digital photography with the Internet to develop a new and inexpensive way to screen for a common childhood oral disease that predominantly plagues America's inner city toddlers - early childhood dental caries (ECC), or as it is commonly called, "baby bottle tooth decay." - Pharmos Commences Dosing In Second Phase 2a Study Of Cannabinor In Experimentally Induced Pain
Pharmos Corporation (Nasdaq: PARS) announced today that it has commenced dosing in a second Phase 2a clinical study of cannabinor (PRS-211,375) for the treatment of pain. The proof-of-concept trial will test for analgesic activity and the safety of cannabinor, a CB2-selective synthetic cannabinoid drug candidate, in healthy subjects experiencing capsaicin-induced pain. - Investigational Drug Targeting Inflammatory Bowel Disease Enters Second Human Clinical Trial
Novogen Limited's investigational anti-inflammatory compound NV-52, is entering its second human clinical study following the successful completion of toxicology testing.
NV-52 is a novel compound developed by Novogen to target inflammatory bowel disease.
This study was cleared to begin following the successful completion of a Phase Ia study that confirmed the bio-availability of the drug in oral form, and its safety when administered at an acute dose. - Gout Increases Risk Of Heart Attack, According To University Of Pittsburgh Study
People with gout are at increased risk of having a heart attack, according to a University of Pittsburgh School of Medicine study published in the August edition of the journal Arthritis & Rheumatism. The article is available on line at http://www3.interscience.wiley.com/cgi-bin/jhome/76509746. This is the first study to show that among men with no previous history of coronary artery disease, gout is a significant independent risk factor of heart attack. - Glimmer Of Hope For Gout Patients
For over 100 years we have known that the intensely painful disease gout is caused by the accumulation of monosodium urate crystals (MSU) in joints. Now, in a study appearing in the August issue of the Journal of Clinical Investigation, Kenneth Rock and colleagues from University of Massachusetts Medical School uncover how these crystal deposits are recognized by the immune system and trigger acute and painful inflammation. - Glimmer Of Hope For Gout Patients
For over 100 years we have known that the intensely painful disease gout is caused by the accumulation of monosodium urate crystals (MSU) in joints. Now, in a study appearing in the August issue of the Journal of Clinical Investigation, Kenneth Rock and colleagues from University of Massachusetts Medical School uncover how these crystal deposits are recognized by the immune system and trigger acute and painful inflammation. - Pain Therapeutics And King Pharmaceuticals Initiate Clinical Program Of A Second Abuse-Resistant
Pain Therapeutics, Inc. (Nasdaq: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) announced today the initiation of a Phase I clinical trial to evaluate the effects of PTI-202 in humans. PTI-202 is a new drug candidate in the companies' collaboration to develop abuse-resistant opioid painkillers, a new category of drugs intended to prevent prescription drug abuse. - ORADUR(TM) Technology Milestone: New ORADUR-based Investigational Drug Candidate Commences Phase I
DURECT Corporation (Nasdaq: DRRX) reported today the initiation of a Phase I clinical trial for a new ORADUR-based opioid drug candidate. This new drug candidate is the second ORADUR-based opioid drug to undergo clinical testing by King Pharmaceuticals, Inc., the company which will be commercializing the drug candidate, if approved, and Pain Therapeutics, Inc. - HEALTHPOINT's Proprietary EXACTACAIN(TM) Spray Topical Anesthetic Can Reduce Risk Of Benzocaine
A 2006 FDA advisory about the dangers associated with possible overdosing and erroneous administration of benzocaine products highlights the value of one product that may be a safer dosing alternative for physicians and their patients --- HEALTHPOINT's EXACTACAIN(TM) (benzocaine 14%, butamben 2%, tetracaine hydrocholoride 2%) Spray Topical Anesthetic. - Back Pain A Common Problem For Nurses
Nurses offer care and comfort, but they often end up with a pain in the back for their efforts, the results of a new study show.
"Nurses suffer from work-related low back pain more often than workers in other professions," said Edgar Vieira, a doctoral student in the University of Alberta Faculty of Rehabilitation Medicine and lead author of the study. - Lower Levels Of Anti-inflammatory Proteins May Contribute To Chronic Widespread Pain
Chronic widespread pain, a common medical condition, can be difficult to treat and is often associated with fatigue, poor sleep and depression. A connection between fibromayalgia (FM) and cytokines (proteins that act as messengers between cells) was suspected after cancer patients treated with the cytokine interleukin -2 developed FM-like symptoms. - DOV Pharmaceutical, Inc. Announces Results Of Carcinogenicity Studies
DOV Pharmaceutical, Inc. (Nasdaq: DOVP) announced today the completed assessment of results from the carcinogenicity studies for its novel analgesic, bicifadine. There were no meaningful signals of carcinogenicity detected after two years of testing in two species -- rats and mice. The Company believes these results are very positive, as this outcome from these two important safety studies will support the ability of DOV to file an NDA with the U.S. - New ITI Study Shows Potential Of Intranasal Midazolam As An Effective, Noninvasive Sedative
Intranasal Therapeutics, Inc. (ITI) announced today that a proof-of-principle study published in the August issue of the peer-reviewed journal Anesthesia & Analgesia demonstrates the potential of intranasally delivered midazolam as a convenient, fast-acting and noninvasive alternative to intravenous and oral forms of this widely used sedative. - Virtual Realities Against Pain
The feeling of pain produced during medical treatment can be reduced through sophisticated virtual reality helmets, a simple computer game and the determined predisposition of the patient. According to research psychologists at the UAB, this type of distraction even reduces the dosage of sedatives. Their research suggests putting greater emphasis on methodology and on psychological aspects of this technique in order to improve its property.
|
